

NANO EXPRESS

Open Access



Facile Approach to Prepare rGO@Fe₃O₄ Microspheres for the Magnetically Targeted and NIR-responsive Chemo-photothermal Combination Therapy

Chunyong Liang^{1†}, Jiyong Song^{1†}, Yongguang Zhang¹, Yaping Guo¹, Meigui Deng², Wei Gao^{3*} and Jimin Zhang^{2*}

Abstract

Near-infrared (NIR)-light responsive graphene have been shown exciting effect on cancer photothermal ablation therapy. Herein, we report on the preparation of Fe₃O₄-decorated hollow graphene microspheres (rGO@Fe₃O₄) by a facile spray drying and coprecipitation method for the magnetically targeted and NIR-responsive chemo-photothermal combination therapy. The microspheres displayed very high specific surface area (~ 120.7 m² g⁻¹) and large pore volume (~ 1.012 cm³ g⁻¹), demonstrating distinct advantages for a high loading capacity of DOX (~ 18.43%). NIR triggered photothermal effect of the rGO@Fe₃O₄ microspheres responded in an on-off manner and induced a high photothermal conversion efficiency. Moreover, The Fe₃O₄ on the microspheres exhibited an excellent tumor cells targeting ability. The chemo-photothermal treatment based on rGO@Fe₃O₄/DOX showed superior cytotoxicity towards Hela cells in vitro. Our studies indicated that rGO@Fe₃O₄/DOX microcapsules have great potential in combined chemo-photothermal cancer treatment.

Keywords: rGO@Fe₃O₄ microspheres, NIR response, Magnetic target, Chemo-photothermal therapy

Introduction

Cancer is one of the most malignant diseases in the world and is a leading cause of human death [1, 2]. Although chemotherapy is commonly used in the clinic cancer treatment, several key issues including low therapeutic efficiency and extensive side effects seriously limit its application [3]. Drug delivery systems (DDS) have shown great advantages in enhancing drug solubility, bioavailability, and tumor accumulation, which are

expected to prominently improve their antitumor efficiency [4]. Recently, hollow microspheres employing as drug delivery systems have gained increasing attention owing to their large surface area and abundant porous structures [5–8], and several hollow microsphere materials have been designed with innovative technologies [9–13].

Graphene oxide (GO), a new type of inorganic free-metallic material, has been widely investigated in drug delivery due to its unique features, such as good biocompatibility, low cost, and simple preparation [14–17]. Notably, graphene oxide can effectively transform light to heat when triggered by NIR irradiation [18–20], becoming a promising strategy to improve the photothermal therapy effect of cancer. Chen group has reported that GO could deliver the anticancer drugs by non-covalent interaction such as π - π stacking, hydrogen bonding, and electrostatic adsorption [21]. However, the 2D graphene

* Correspondence: doctorgao99@163.com; zhangjimin@hebut.edu.cn

[†]Chunyong Liang and Jiyong Song contributed equally to this work.

³Key Laboratory of Cancer Prevention and Therapy, Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

²Hebei Key Laboratory of Functional Polymers, National-Local Joint Engineering Laboratory for Energy Conservation of Chemical Process Integration and Resources Utilization, School of Chemical Engineering and Technology, Hebei University of Technology, Tianjin 300130, China
Full list of author information is available at the end of the article

oxide nanosheet tends to agglomerate due to the large specific surface as well as the van der Waals bonds among the graphene layers [17, 22], resulting in poor solubility in water and decreasing drug loading ability. Some strategies have been explored to overcome these shortcomings. Tsukruk group has developed a graphene hollow capsules using layer-by-layer assembly technology [23], which showed an extremely high drug loading compared to other GO materials. This could be contributed to the high specific surface area and large pore volume of the hollow capsule stabilized by GO. However, few reports have referred to the study of GO with a three-dimensional-connected pore structure for drug delivery.

Although many reported drug delivery systems have exhibited superior drug loading ability and controlled drug release behavior, their preclinical research and applications are also limited due to an insufficient specificity to target tumor tissues [24]. Among various drug target delivery systems, Fe_3O_4 , a magnetic-target material is widely used in cancer therapy for its high magnetic responses, stable quality, and easy achievement [25–29]. Ni group has developed an $\text{Fe}_3\text{O}_4@/\text{SiO}_2$ core-shell structure nanoparticles with superparamagnetic property for magnetic targeting of tumors [30]. Furthermore, Fe_3O_4 anchored GO nanoparticles have been well studied in combination of magnetic target delivery and photothermal therapy [31–34].


In the present study, we report an advanced strategy for developing a DDS platform comprising an iron oxide decorated rGO hollow microspheres ($\text{rGO}@/\text{Fe}_3\text{O}_4$) for the magnetically targeted and NIR triggered

photothermal therapy (PTT). As depicted in Scheme 1, $\text{rGO}@/\text{Fe}_3\text{O}_4$ hollow microspheres were prepared through three steps. Firstly, $\text{rGO}-\text{SiO}_2$ is synthesized by spray drying method using SiO_2 as a template and then rGO hollow microspheres were obtained by removing SiO_2 with HF etching. Afterward, Fe_3O_4 nanoparticles were anchored onto rGO hollow microspheres to construct $\text{rGO}@/\text{Fe}_3\text{O}_4$ microspheres. In this system, rGO is served as a NIR-triggered PTT agent, and Fe_3O_4 can offer the magnetic targeting property towards to HeLa cell. Doxorubicin (DOX), encapsulated microspheres ($\text{rGO}@/\text{Fe}_3\text{O}_4/\text{DOX}$) based on pore adsorption and π - π stacking, is expected to exhibit ultrahigh drug loading capacity and pH-responsive drug release behavior, and can significantly enhance the anticancer effect for the combination of photothermal-chemotherapy.

Materials and Methods

Materials

Iron chloride hexahydrate ($\text{FeCl}_3 \cdot \text{H}_2\text{O}$), sodium hydroxide (NaOH), and ferrous sulfate heptahydrate ($\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$) were purchased from Sinopharm Chemical Reagent Co., Ltd. HeLa cells are from Tianjin Cancer Hospital. Phosphate buffered saline (PBS), Doxorubicin hydrochloride (DOX-HCl), Dulbecco's minimum essential medium (DMEM), 4',6-diamidino-2-phenylindole (DAPI), and cell counting kit-8 (CCK-8) were purchased from Solarbio Science and Technology Co., Ltd. SiO_2 (~300 nm) was purchased from Shanghai Yuanjiang Chemical Company. Graphene oxide deion water solution (2 mg/ml) was a commercially available product from Nanjing Xianfeng Company.



Preparations of rGO@Fe₃O₄ Microspheres

Hollow graphene microspheres were prepared via spray drying method using SiO₂ (300 nm) as the template. Briefly, 100 mL SiO₂ suspension liquid (50 mg mL⁻¹) was slowly dropped into 300 mL GO aqueous solution (2 mg mL⁻¹) under drastic stirring, the mixed solution was spray dried at 200 °C in a spray dryer unit. Subsequently, the product was kept at 300 °C under Ar protection for 2 h and rGO-SiO₂ was obtained. To remove SiO₂, rGO-SiO₂ was placed in HF solution (10%) for 48 h at 60 °C. The solid product was washed several times and dried in a vacuum drying oven at 60 °C for 12 h, rGO was finally obtained with a yield of 75%.

The rGO@Fe₃O₄ nanoparticles were prepared via the coprecipitation method. In a typical process for the synthesis of rGO@Fe₃O₄ nanoparticles, 0.27 g FeCl₃·H₂O, 0.28 g FeSO₄·7H₂O, and 0.1 g rGO hollow microspheres were dissolved in 10 mL deionized water and stirred for 30 min at 50 °C. Then, 60 mL NaOH (0.15 mol L⁻¹) was slowly added under continuous stirring at 50 °C for 12 h. The products were finally separated magnetically and washed repeatedly with deionized water and ethanol several times followed by drying at 60 °C under vacuum for 12 h.

Structural Characterization

The size and morphology of the sample were analyzed using a field emission scanning electron microscopy (FE-SEM, Hitachi, S-4800) and transmission electron microscopy (TEM, JEM2100F, JEOL). The composition of the products was analyzed via X-ray diffraction system (XRD, D8 Focus, Cu Ka radiation, Bruker, Germany) at a scan rate of 12 °/min range from 10 to 80°. Also, X-ray photoelectron spectroscopy (XPS) was carried out on a XPS spectrometer (Thermo Fisher Scientific, ESCALAB 250Xi, America). The FTIR (FT-IR, AVATAR360, Nicolet) were recorded from 500 to 4000 cm⁻¹ at a resolution of 4 cm⁻¹. Magnetic measurements were performed using a superconducting quantum interference device (SQUID, Quantum Design MPMS) magnetometer at room temperature (300 K). The Raman spectra were collected using a Raman spectroscope (Renishaw, inVia Reflex, England) with a 532 nm wavelength laser. The content of rGO was evaluated using a thermogravimetric analyzer (TGA, TA Instruments-water LLC, SDTQ-600). The specific surface area was measured using the Brunauer-Emmett-Teller (BET) technique. UV-Vis spectra were recorded using a Beckman DU 800 nucleic acid/protein analyzer (Beckman Instruments, Inc., Rosemead, CA).

DOX Loading and Release

DOX, a model chemotherapeutic drug doxorubicin, was encapsulated into the cores of rGO@Fe₃O₄ to evaluate

the loading and releasing behaviors of anticancer drugs in vitro. rGO@Fe₃O₄/DOX was prepared according to the previous reference. In brief, 10 mL (0.2 mg mL⁻¹) of DOX aqueous solution was added to 10 mg of rGO@Fe₃O₄ solution, the mixture was ultrasonically homogenized to insure no significant precipitation. Then, the mixture was equilibrated on a reciprocating shaker (SK-O180-Pro) at a speed of 150 rpm for 24 h. After centrifugation at 6000 rpm for 10 min, unloaded DOX was removed, the supernatant of rGO@Fe₃O₄/DOX was measured via UV-Vis spectrophotometer to determine the amount of DOX loaded. The OD of DOX was recorded at 490 nm, the following equations were used to calculate the loading efficiency (LE) and loading capacity (LC) of the DOX:

$$LE = (\text{total amount of DOX} - \text{Free DOX}) / \text{total amount of DOX}$$

$$LC = (\text{total amount of DOX} - \text{Free DOX}) / \text{amount of rGO@Fe}_3\text{O}_4/\text{DOX}$$

The in vitro release studies of DOX was performed by putting rGO@Fe₃O₄/DOX (10 mg) in a dialysis bag (MWCO = 1000) with phosphate-buffered saline (PBS, 30 mL) at pH 5.4, 6.5, or 7.4, placing it in a 37 °C water bath and shaking at 80 rpm. At predetermined intervals, 3 mL of the release medium was collected and the amount of released DOX was calculated by measuring the UV-Vis at 480 nm.

NIR-Triggered Photothermal Effect of rGO@Fe₃O₄ Microspheres

To monitor the influence of rGO@Fe₃O₄ dose on NIR-triggered photothermal effect, the rGO@Fe₃O₄ solutions with different concentrations (0.0625, 0.125, 0.25, 0.5, and 1 mg mL⁻¹) were irradiated with NIR laser at 2 W cm⁻² for 5 min, respectively. Furthermore, the influence of NIR energy on the photothermal effect was evaluated by irradiating rGO@Fe₃O₄ (0.25 mg mL⁻¹) with different powers (1 W cm⁻², 1.5 W cm⁻², 2 W cm⁻²) for 5 min. The real-time temperature was measured using a FLIR I5 infrared thermal camera.

In Vitro Uptake

Hela cells were seeded in 35 mm² confocal dishes at a density of 1 × 10⁵ cells/well. After incubating for 24 h in an incubator (5% CO₂, 37 °C), the medium was removed, and the fresh medium containing rGO@Fe₃O₄/DOX microspheres and rGO@Fe₃O₄/DOX with magnet were added and cultivated for another 5 h. The rGO@Fe₃O₄/DOX concentration was 0.1 mg mL⁻¹. The cells were then washed three times with cold PBS (pH = 7.4) and fixed with 4% paraformaldehyde solution for 20 min (CLSM, TCSSP5II, Leica, Ernst-Leitz-Strasse, Germany).

Cell Viability Assays

The cytotoxicity of these microspheres was evaluated by a CCK-8 assay after NIR treatment. HeLa cells were seeded onto 96-well plates (5×10^3 cells/well) in 100 μL of the medium and cultured in 5% CO_2 at 37 $^\circ\text{C}$ for 24 h. For the biocompatibility assessment, $\text{rGO@Fe}_3\text{O}_4$ were added to the well with a concentration range from 0.01 to 0.2 mg mL^{-1} ; for the single photothermal therapy group, $\text{rGO@Fe}_3\text{O}_4$ was added with a concentration range from 0.01 to 0.2 mg mL^{-1} , and applying NIR light irradiation for 10 min (2 W cm^{-2} , 808 nm); for the combined photothermal-chemotherapy group, $\text{rGO@Fe}_3\text{O}_4/\text{DOX}$ was added with a concentration range of

$\text{rGO@Fe}_3\text{O}_4/\text{DOX}$ from 0.01 to 0.2 mg mL^{-1} , and applying NIR light illumination for 10 min (2 W cm^{-2} , 808 nm). The cells were proceeding incubated for 24 h or 48 h. Afterward, the cells were washed with PBS and incubated in 100 μL DMEM medium containing 10 μL CCK-8 solution for another 40 min. The viability was detected using a microplate reader at a wavelength of 450 nm. All the experiments were conducted in triplicate.

Results and Discussions

Synthesis and Morphology Characterization

The preparation of $\text{rGO@Fe}_3\text{O}_4$ microspheres was performed through three steps. Firstly, rGO-SiO_2





Fig. 1 Morphology characterization of microspheres. SEM images of (a) rGO-SiO_2 , (b) rGO , (c) $\text{rGO@Fe}_3\text{O}_4$; TEM images of (d) rGO-SiO_2 , (e) rGO , (f) $\text{rGO@Fe}_3\text{O}_4$; hydrodynamic size distribution of the corresponding samples (g) rGO-SiO_2 , (h) rGO , (i) $\text{rGO@Fe}_3\text{O}_4$

microspheres were synthesized by spray drying using SiO_2 as a template. The morphology of rGO-SiO_2 microspheres was characterized by SEM and TEM. As shown in Fig. 1a, the rGO-SiO_2 microspheres with diameters of $3\ \mu\text{m}$ exhibited uniform spherical shape and comprised of many crowded SiO_2 nanoparticles ($\sim 300\ \text{nm}$). The TEM data and the hydrodynamic diameter measured by dynamic light scattering also confirmed the results. (Fig. 1d, g). Then, hollow rGO microspheres were obtained by

removing SiO_2 from rGO-SiO_2 with heating at $300\ ^\circ\text{C}$ and HF etching. Obvious pores with a pore size of about $300\ \text{nm}$ could be observed due to SiO_2 dissolution (Fig. 1b, e). Finally, Fe_3O_4 in virtue of magnetic targeted ability was decorated onto the porous rGO by the coprecipitation method. The observation of SEM and TEM illustrated that the remarkable decrease of pore size after Fe_3O_4 loading was obtained, (Fig. 1c, f), providing the feasibility of drug delivery and the controlled drug release. Notably, the



particle size and hydrodynamic size distribution of rGO-SiO₂, rGO, rGO@Fe₃O₄ have no more visible changes during these treatments (Fig. 1g, h, i).

Structure and Composition Characterization

To further confirm the successful preparation of rGO@Fe₃O₄, SEM with EDS was employed to investigate the structure and composition of the microspheres. The EDS images of rGO@Fe₃O₄ were characterized by visualizing the inelastically scattered electrons in the energy loss windows for elemental O, Fe, and C, and the different color areas represent O, Fe, and C enriched locations in real structures, respectively. As shown in Fig. 2a and b, Fe and O were widely distributed in rGO@Fe₃O₄ microspheres with high loading density. Figure 2d confirmed that the Fe₃O₄ nanoparticles uniformly dispersed in the rGO with a diameter of about 18 nm, resulting in a sharp decrease of pore size in rGO@Fe₃O₄ microspheres. The selected area electron diffraction (SAED) pattern further verified the presence of Fe₃O₄ in rGO (Fig. 2e), the characteristic resonance in 2.98 nm, 2.53 nm, 2.09 nm, and 1.49 nm face spacing assigned to the 220, 311, 400, 511, and 440 planes of the face-centered-cubic phase of Fe₃O₄, respectively. The peaks

appeared at 220, 311, 400, 511, and 440 corresponding to Fe₃O₄ were also detected in the XRD spectra, which was consistent with SAED results (Fig. 2c). However, it is reported that Fe₃O₄ and γ -Fe₂O₃ could not be distinguished by the XRD pattern independently for the same location of characteristic peaks [35]. XPS result showed that the predominant peaks at 725.9/724.5 eV and 714.1/711.0 eV, corresponding to Fe2p_{1/2} and Fe 2p_{3/2} of the rGO@Fe₃O₄ (Fig. 2g, h), respectively, indicating the co-existence of Fe³⁺ and Fe²⁺ in Fe₃O₄ [36]. Thermogravimetric (TGA) analysis was performed to monitor the thermal degradation behavior of rGO in rGO@Fe₃O₄ microspheres by heating the sample to 800 °C and cooling down to 100 °C in an air atmosphere (Fig. 2f). The mass loss curve showed two distinct mass loss regions including the dehydration region (40–300 °C) and the devolatilization region (300–800 °C) of rGO in rGO@Fe₃O₄, carbon content calculated from the sample was 25.6 wt.%.

The magnetic properties of rGO@Fe₃O₄ microspheres were investigated using a superconducting quantum interference device. The magnetic field was conducted with a scanning range from –20,000 to 20,000 Oe at room temperature. Figure 2i shows the saturation magnetization (Ms) value and coercive field





Fig. 3 Photothermal effects of rGO@Fe₃O₄. **a** Concentration-dependent temperature change of rGO@Fe₃O₄ solutions at different concentrations (0.0625, 0.125, 0.25, 0.5, and 1 mg mL⁻¹) under 808 nm irradiation at 2 W cm⁻² for 5 min. **b** Power-dependent temperature response of 0.25 mg mL⁻¹ rGO@Fe₃O₄ solution under the irradiation of an 808 nm NIR laser for 5 min (1 W cm⁻², 1.5 W cm⁻², 2 W cm⁻²). **c** Infrared thermal images of rGO@Fe₃O₄ solution at 0, 1, 2, 3, 4, and 5 min intervals stimulated at 808 nm (2 W cm⁻²). **d** Temperature increases of rGO@Fe₃O₄ (0.25 mg mL⁻¹) solution during 6 successive cycles of laser on/off under 808 nm irradiation at 2 W cm⁻²

(Hc) value of Fe_3O_4 are 66.6 emu g^{-1} and 9.3 Oe . After loading Fe_3O_4 onto rGO, the Ms value and Hc value of the $\text{rGO@Fe}_3\text{O}_4$ microspheres decreased to 33.9 emu g^{-1} and 7.44 Oe . The remarkably decrease in magnetic saturation can be contributed to the diamagnetic properties of rGO in $\text{rGO@Fe}_3\text{O}_4$ microspheres. Moreover, The selective agglomeration ability of $\text{rGO@Fe}_3\text{O}_4$ microspheres was performed intuitively by magnetic separation experiment. The suspensions of the Fe_3O_4 and $\text{rGO@Fe}_3\text{O}_4$ microspheres were put into the vial with an external magnet for 2 min, the suspensions can be concentrated to the magnet side and the aqueous solution became transparent. When the magnet was taken away, the $\text{rGO@Fe}_3\text{O}_4$ microspheres were dispersed uniformly again after slowly

shaking, indicating that $\text{rGO@Fe}_3\text{O}_4$ microspheres holding the merit of good water-dispersive ability. The excellent water-dispersive ability and magnetic response property paved the way for the magnetic targeted application of $\text{rGO@Fe}_3\text{O}_4$ as drug carries in cancer treatment.

Photothermal Effect Analysis

Considering the deeper penetration into the tissue and less damage to surrounding tissues of NIR, NIR-responsive photothermal therapy was often employed to tumor treatment. Hence, the photothermal transformation behavior of $\text{rGO@Fe}_3\text{O}_4$ aqueous solutions at different concentrations and different power densities were recorded under NIR laser irradiation at 808 nm for 5 min. Figure 3a, b showed




that the temperature increase of $\text{rGO@Fe}_3\text{O}_4$ was highly dependent on the concentration and the laser power density. When the concentration of the microspheres was up to 1 mg mL^{-1} , the temperature raised up from 27.9 to 70.3°C under NIR laser irradiation for 5 min at 2 W cm^{-2} , while the temperature for PBS group just raised up from 31.7 to 36.2°C . The high photothermal conversion efficiency of $\text{rGO@Fe}_3\text{O}_4$ will have a great potential for tumor photothermal therapy according to previous report that protein degeneration and DNA damage in cell will happen (happened) upon exposure to 50°C for 4 to 6 min [21, 37]. To intuitively display the photothermal transformation behavior of $\text{rGO@Fe}_3\text{O}_4$, IR thermography was performed and the results were shown in Fig. 4c. The $\text{rGO@Fe}_3\text{O}_4$ solution with the concentration of 1 mg mL^{-1} was quickly increased to 70.3°C after NIR irradiation for 5 min, while the water group has no obvious changes, which was consistent with the thermometry results. Furthermore, the photothermal stability of the $\text{rGO@Fe}_3\text{O}_4$ was studied by performing laser on/off procedure with an 808 nm laser at 2 W cm^{-2} for six cycles (Fig. 3d). The identical temperature increase was obtained, indicating the perfect NIR photothermal stability of $\text{rGO@Fe}_3\text{O}_4$

composites. These results demonstrated that $\text{rGO@Fe}_3\text{O}_4$ microspheres holding great promise as a photothermal agent for photothermal therapy in cancer.

Drug Loading and Release

The surface area and pore-size of $\text{rGO@Fe}_3\text{O}_4$ were evaluated by BET and BJH analyses (Fig. 2a, b). N_2 adsorption-desorption curve type was isothermal IV type, and the surface area and pore size were $120.7 \text{ m}^2 \text{ g}^{-1}$, 2–8 nm and $1.012 \text{ cm}^3 \text{ g}^{-1}$, respectively. The results showed that $\text{rGO@Fe}_3\text{O}_4$ possessed mesoporous channels and average pore size distribution, exhibiting great potential for anti-tumor drug loading. Then, the $\text{rGO@Fe}_3\text{O}_4$ microspheres with porous structure were served to load a model chemotherapeutic drug doxorubicin by simply mixing and slight sonication. The ATR-FTIR analysis further verified the stable incorporation of DOX in $\text{rGO@Fe}_3\text{O}_4$ due to the characteristic resonance of $-\text{COOH}$ and benzene groups of DOX at 1726 cm^{-1} and 1618 cm^{-1} (Fig. 4c). Scanning electron microscopy (SEM) observation showed that the new signals of N elements assigned to DOX distributed uniformly in microsphere after DOX loading (Fig. 4d, e). Moreover, the DOX loading efficiency



(LE) and loading capacity (LC) of $rGO@Fe_3O_4/DOX$ were 92.15% and 18.43%, respectively. The remarkably higher LCs of $rGO@Fe_3O_4/DOX$ than many drug-carriers can be contributed to extremely high surface areas and pore sizes [19]. The high LE of $rGO@Fe_3O_4/DOX$ may be attributed to two aspects, one is that $rGO@Fe_3O_4$ can interact with DOX by strong π - π stacking between sp^2 -hybridized π bonds of $rGO@Fe_3O_4$ and the quinone portion of DOX [21], and another one may be that they can form hydrogen bonding between the carboxylic acid ($-COOH$), hydroxyl ($-OH$) groups of $rGO@Fe_3O_4$ and the amine ($-NH_2$), hydroxyl ($-OH$) groups of DOX. Then, we monitored DOX release behavior in PBS at pH 7.4, 6.5, and 5.4, to mimic the extracellular environments of tumor and normal tissues. As indicated in Fig. 4f, the release rate of DOX was accelerated when the pH was adjusted from 7.4 to 5.4, and the sustained DOX release at pH 5.4 can be up to 73% after 98 h treatment. Therefore, the cumulative release profile of DOX from $rGO@Fe_3O_4$ exhibited a pH-dependent manner. This accelerated release under acidic conditions could be due to the partial protonation of the hydroxyl and amine groups of DOX, leading to higher drug solubility and weakening of hydrogen bonds between DOX and graphene [38]. Furthermore, we also studied the NIR-responsive DOX release behavior in vitro. As indicated in Fig. 4g, DOX release was accelerated by NIR-

radiation and the release rate of DOX was up to 85%. This pH and NIR stimuli-responsive behavior plays an important role in effective drug delivery towards the tumor site.

In Vitro Cell Uptake

To verify the magnetic targeting ability of Fe_3O_4 in $rGO@Fe_3O_4$ microsphere, the cellular uptake experiments with or without magnetic field treatment was qualitatively investigated by confocal laser scanning microscopy (CLSM). Hela cells were incubated with $rGO@Fe_3O_4/DOX$ for 4 h and the nuclei of Hela were stained by DAPI. The results in Fig. 5 showed that the black spot corresponding to $rGO@Fe_3O_4$ microsphere and obvious intracellular red fluorescence signals assigned to DOX were observed in the $rGO@Fe_3O_4$ group with a magnetic field treatment. In contrast, there was less black spot and weaker DOX fluorescence can be found when $rGO@Fe_3O_4$ group without magnetic field loading. The explanation may be that the black spot attributed to $rGO@Fe_3O_4$ internalized into the cell could be promoted by magnet. The results indicate that Fe_3O_4 in $rGO@Fe_3O_4/DOX$ could specifically target Hela cells efficiently and significantly enhance the cell internalization of microspheres, demonstrating favorable magnetic targeting ability of the drug delivery system in cancer therapy.




Fig. 6 The biocompatibility and the therapeutic efficacy of single photothermal therapy or combined photothermal-chemotherapy. **a** Cell viability of Hela cells cultured with $rGO@Fe_3O_4$ for 24 h and 48 h. **b** Cell viability of Hela cells cultured with or without NIR irradiation at different concentrations of $rGO@Fe_3O_4$ for 24 h and 48 h. **(c, d)** Cell viability of Hela cells cultured with free DOX, $rGO@Fe_3O_4/DOX$ microspheres for 24 h and 48 h with and without NIR irradiation (808 nm, 2 W cm^{-2}) (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$)

In Vitro Cytotoxicity Analyses

The biocompatibility of rGO@Fe₃O₄ was evaluated using CCK-8 assay towards Hela cells. As shown in Fig. 6a, after incubation with rGO@Fe₃O₄ at a wide range of different concentrations, the cell viability was also higher than 90% even at high concentrations up to 200 μg mL⁻¹, the results indicated that rGO@Fe₃O₄ exhibits a high biocompatibility and could be served as an efficient drug delivery platform. The photothermal therapy efficacy of rGO@Fe₃O₄ was further investigated after incubation with Hela cells for 24 h and 48 h under NIR light irradiation (808 nm NIR laser, 10 min). As shown in Fig. 6b, the phototoxicity was clearly dose-dependent upon NIR stimulation, and cell viability decreased from 90.37 to 35.52% at 24 h, and from 93.77 to 31.75% at 48 h, implying that rGO@Fe₃O₄ had excellent phototoxicity and hold great promise in photothermal therapy. To estimate the synergic therapeutic efficacy of photothermal-chemotherapy, the cytotoxicity of rGO@Fe₃O₄/DOX towards Hela cells with and without NIR irradiation were studied. As shown in Fig. 6c, d, the cell viability showed concentration-dependent and time-controlled manner. Approximately 65% and 80% of Hela cells were killed by rGO@Fe₃O₄/DOX without NIR irradiation and DOX at 24 h, the decreased tumor-killing ability of rGO@Fe₃O₄/DOX compared to free DOX may be due to the delayed DOX release behavior of rGO@Fe₃O₄/DOX microspheres. After NIR laser irradiation (808 nm NIR laser, 10 min), rGO@Fe₃O₄/DOX with laser group killed more than 86% cells at an equivalent dose of DOX (30 μg mL⁻¹). Similar results could be observed after the same treatment cells for 48 h, the decrease in the cell viability of DOX, rGO@Fe₃O₄/DOX, rGO@Fe₃O₄/DOX with NIR irradiation group was 80%, 76%, and 90%, respectively, indicating a synergistic effect of the combined photothermal therapy and chemotherapy.

Conclusions

In summary, we explored a facile strategy to construct rGO-based drug delivery platform rGO@Fe₃O₄/DOX for synergistic photothermal-chemotherapy. rGO@Fe₃O₄/DOX microsphere exhibited excellent NIR-triggered PTT effect and perfect NIR photothermal stability. The Fe₃O₄ on the microspheres ensured excellent tumor cells targeting ability. DOX could be encapsulated into rGO@Fe₃O₄ with an ultrahigh drug-loading capacity and a pH-responsive drug release behavior could be simultaneously achieved. In addition, an enhanced antitumor efficiency was achieved when a combination of chemotherapy and photothermal therapy. Therefore, this multifunctional drug delivery platform could be a promising candidate for tumor targeting and combinatorial cancer therapy in the future.

Abbreviations

DDS: Drug delivery system; NIR: Near-infrared; GO: Graphene oxide; DOX: Doxorubicin; DMEM: Dulbecco's minimum essential medium; DAPI: 4',6-diamidino-2-phenylindole; CCK-8: Cell counting kit-8; SEM: Scanning electron microscopy; TEM: Transmission electron microscope; XRD: X-ray diffraction system; XPS: X-ray photoelectron spectroscopy; FTIR: Fourier transform infrared spectroscopy; TGA: Thermogravimetric analyzer; LE: Loading efficiency; LC: Loading capacity

Acknowledgements

The authors appreciated Dr. Weiwei and Wang for proofreading of the manuscript.

Authors' Contributions

Chunyong Liang and Jiying Song performed the experiments and analyzed the experimental data. Yongguang Zhang and Yaping Guo drafted the manuscript. Wei Gao and Jimin Zhang conceived the idea, supervised the execution, and corrected the manuscript. All authors read and approved the final manuscript.

Authors' Information

Not applicable.

Funding

The authors are grateful for the financial support from the National Natural Science Fund Grant (grant number: 51771069) and Tianjin Medical University Cancer Institute and Hospital Key Projects (grant number: 1711).

Availability of Data and Materials

The data and the analysis in the current work are available from the corresponding authors on reasonable request.

Competing Interests

The authors declare that they have no competing interests.

Author details

¹Research Institute for Energy Equipment Materials, Tianjin Key Laboratory of Materials Laminating Fabrication and Interface Control Technology, School of Materials Science & Engineering, Hebei University of Technology, Tianjin 300130, China. ²Hebei Key Laboratory of Functional Polymers, National-Local Joint Engineering Laboratory for Energy Conservation of Chemical Process Integration and Resources Utilization, School of Chemical Engineering and Technology, Hebei University of Technology, Tianjin 300130, China. ³Key Laboratory of Cancer Prevention and Therapy, Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.

Received: 20 November 2019 Accepted: 5 March 2020

Published online: 17 April 2020

References

1. Wong SHM, Kong WY, Fang CM, Loh HS, Chuah LH, Abdullah S, Ngai SC (2019) The TRAIL to cancer therapy: hindrances and potential solutions. *Critical Reviews in Oncology/Hematology* 143:81–94
2. Hussien NA, Isjklan N, Türk M (2018) Aptamer-functionalized magnetic graphene oxide nanocarrier for targeted drug delivery of paclitaxel. *Mater Chem Phys* 211:479–488
3. Wang M, Liu W, Zhang Y, Dang M, Zhang Y, Tao J, Teng Z (2019) Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer. *J Colloid and Interface Sci* 538:630–637
4. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST (2017) Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. *Advanced Drug Delivery Reviews* 108:25–38
5. Ni G, Yang G, He Y, Li X, Du T, Xu L, Zhou S (2020) Uniformly sized hollow microspheres loaded with polydopamine nanoparticles and doxorubicin for local chemo-photothermal combination therapy. *Chem Eng J* 379:122317
6. Kesavan MP, Vinoth Kumar GG, Dhaweethu Raja J, Anitha K, Karthikeyan S, Rajesh J (2017) DNA interaction, antimicrobial, antioxidant and anticancer

- studies on Cu (II) complexes of luotonin A. *J Photochem Photobiol B* 167: 20–28
7. Lou XW, Archer LA, Yang ZC (2008) Hollow micro-/nanostructures: synthesis and applications. *Adv Mater* 20(21):3987–4019
 8. Liu P, Yang D, Chen H, Gao Y, Li H (2013) Discrete and dispersible hollow carbon spheres for PtRu electrocatalyst support in DMFCs. *Electrochimica Acta* 109:238–244
 9. Yue Q, Zhang Y, Wang C, Wang X, Sun Z, Hou X, Zhao D, Deng Y (2015) Magnetic yolk-shell mesoporous silica microspheres with supported Au nanoparticles as recyclable high-performance nanocatalysts. *J Mater Chem A* 3(8):4586–4594
 10. Creixell M, Peppas NA (2012) Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. *Nano Today* 7:367–379
 11. Veisoh O, Kievit FM, Ellenbogen RG, Zhang MQ (2011) Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. *Advanced Drug Delivery Reviews* 63(8):582–596
 12. Yue Q, Li J, Luo W, Zhang Y, Elzathary AA, Wang X, Wang C, Li W, Cheng X, Alghamdi A, Abdullah AM, Deng Y, Zhao D (2015) An interface coassembly in biliquid phase toward core-shell magnetic mesoporous silica microspheres with tunable pore size. *Journal of the American Chemical Society* 137(41):13282–13289
 13. Wang C, Chen J, Zhou X, Li W, Liu Y, Yue Q, Xue Z, Li Y, Elzathary AA, Deng Y, Zhao D (2015) Magnetic yolk-shell structured anatase-based microspheres loaded with Au nanoparticles for heterogeneous catalysis. *Nano Res* 8(1): 238–245
 14. Hortêncio Munhoz JA, Romero FM, de Arruda KH, Dias Moreno G, Oliva de Oliveira M, Meneghetti Peres R, Filipe Carmelino Cardoso Sarmento B (2019) Synthesis of pseudoboehmite-graphene oxide for drug delivery system. *Mater Today Proc* 14:700–707
 15. Tiwari H, Karki N, Pal M, Basak S, Kumar Verma R, Bal R, Gopal Sahoo N (2019) Functionalized graphene oxide as a nanocarrier for dual drug delivery applications: the synergistic effect of Quercetin and Gefitinib against ovarian cancer cells. *Colloids Surf B Biointerfaces* 178:452–459
 16. Chen K, Ling Y, Cao C, Li X, Chen X, Wang X (2016) Chitosan derivatives/reduced graphene oxide/alginate beads for small-molecule drug delivery. *Materials Science and Engineering: C* 69:1222–1228
 17. Xie M, Zhang F, Peng H, Zhang Y, Li Y, Xu Y, Xie J (2019) Layer-by-layer modification of magnetic graphene oxide by chitosan and sodium alginate with enhanced dispersibility for targeted drug delivery and photothermal therapy. *Colloids and Surfaces B: Biointerfaces* 176:462–470
 18. Kasprzak A, Poplawska M (2018) Recent developments in the synthesis and applications of graphene-family materials functionalized with cyclodextrins. *Chemical Communications* 54(62):8547–8562
 19. Liu W, Zhang X, Zhou L, Shang L, Su Z (2018) Reduced Graphene Oxide (rGO) Hybridized Hydrogel as a Near-infrared (NIR)/pH Dual-responsive Platform for Combined Chemo-Photothermal Therapy. *Journal of Colloid and Interface Science* 536:160–170
 20. Golzar H, Yazdian F, Hashemi M, Omid M, Mohammadrezaei D, Rashedi H (2018) Optimizing the hybrid nanostructure of functionalized reduced graphene oxide/silver for highly efficient cancer nanotherapy. *New Journal of Chemistry* 42(15):13157–13168
 21. Hu Y, Sun D, Ding J, Chen L, Chen X (2016) Decorated reduced graphene oxide for photo-chemotherapy. *Journal of Materials Chemistry B* 4(5):929–937
 22. Zhang C, Huang S, Tjiu WW, Fan W, Liu T (2012) Facile preparation of water-dispersible graphene sheets stabilized by acid-treated multi-walled carbon nanotubes and their poly(vinyl alcohol) composites. *J Mater Chem*. 22(6): 2427–2434
 23. Ye C, Combs ZA, Calabrese R, Dai H, Kaplan DL, Tsukruk VV (2014) Robust microcapsules with controlled permeability from silk fibroin reinforced with graphene oxide. *Small* 10:5087–5097
 24. Findlay VJ (2004) Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. *Mol Pharmacol* 65(5):1070–1079
 25. Shen L, Li B, Qiao Y (2018) Fe₃O₄ nanoparticles in targeted drug/gene delivery systems. *Materials* 11(2):324
 26. He K, Ma Y, Yang B, Liang C, Chen X, Cai C (2017) The efficacy assessments of alkylating drugs induced by nano-Fe₃O₄/CA for curing breast and hepatic cancer. *Acta A* 173:82–86
 27. Shahabadi N, Akbari A, Jamshidbeigi M, Falsafi M (2016) Functionalization of Fe₃O₄@SiO₂ magnetic nanoparticles with nicotinamide and in vitro DNA interaction. *Mol Liq* 224:227–233
 28. Xing R, Liu G, Zhu J, Hou Y, Chen X (2014) Functional magnetic nanoparticles for non-viral gene delivery and MR imaging. *Pharm. Res* 31: 1377–1389
 29. Saei AA, Barzegari A, Majd MH, Asgari D, Omid Y (2014) Fe₃O₄ nanoparticles engineered for plasmid DNA delivery to *Escherichia coli*. *J Nanopart* 16:1–11
 30. Zhao Y, Qiu Z, Huang J (2008) Preparation and analysis of Fe₃O₄ magnetic nanoparticles used as targeted-drug carriers. *Chinese Journal of Chemical Engineering* 16(3):451–455
 31. Chen W, Yi P, Zhang Y, Zhang L, Deng Z, Zhang Z (2011) Composites of aminodextran-coated Fe₃O₄ nanoparticles and graphene oxide for cellular magnetic resonance imaging. *ACS Applied Materials & Interfaces* 3(10): 4085–4091
 32. Yang K, Hu L, Ma X, Ye S, Cheng L, Shi X (2012) Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. *Advanced Materials* 24(14):1868–1872
 33. Ma X, Tao H, Yang K, Feng L, Cheng L, Shi X (2012) A functionalized graphene oxide-iron oxide nanocomposite for magnetically targeted drug delivery, photothermal therapy, and magnetic resonance imaging. *Nano Res* 5(3):199–212
 34. Peng E, Ding J, Xue JM (2014) Concentration-dependent magnetic hyperthermic response of manganese ferrite-loaded ultrasmall graphene oxide nanocomposites. *New J Chem*. 38(6):2312–2319
 35. De Bonis A, Lovaglio T, Galasso A, Santagata A, Teghil R (2015) Iron and iron oxide nanoparticles obtained by ultra-short laser ablation in liquid. *Appl Surface Sci* 353:433–438
 36. Jiao JQ, Qiu WD, Tang JG, Chen LP, Jing LY (2016) Synthesis of well-defined Fe₃O₄ nanorods/N-doped graphene for lithium-ion batteries. *Nano Res* 9:1256–1266
 37. Zhou M, Liu S, Jiang Y, Ma H, Shi M, Wang Q, Xing MMQ (2015) Doxorubicin-loaded single wall nanotube thermo-sensitive hydrogel for gastric cancer chemo-photothermal therapy. *Adv Funct Mater* 25(29):4730–4739
 38. Huang YC, Arham M, Jan JS (2013) Bioactive vesicles from saccharide- and hexanoyl-modified poly(L-lysine) copolypeptides and evaluation of the cross-linked vesicles as carriers of doxorubicin for controlled drug release. *European Polymer Journal* 49(3):726–737.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)